Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms
Primary Purpose
Pancreatic Neoplasm
Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Robotic pancreaticoduodenectomy
Laparoscopic pancreaticoduodenectomy
Robotic Distal Pancreatectomy
Laparoscopic Distal Pancreatectomy
Sponsored by
About this trial
This is an interventional treatment trial for Pancreatic Neoplasm
Eligibility Criteria
Inclusion Criteria:
- 18 years old or older;
- Diagnosed as PCN;
- Patients with head or neck PCNs are eligible for minimal invasive PD, or patients with distal PCNs are eligible for minimal invasive DP.
Exclusion Criteria:
- Not a PCN base on the sample's pathology;
- Procedure change from MIDP/MIPD to others during the operation;
- ASA more than 4;
- Patients or families deny certain treatment.
Sites / Locations
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Active Comparator
Experimental
Active Comparator
Arm Label
MIPD-ROB
MIPD-LAP
MIDP-ROB
MIDP-LAP
Arm Description
Patients with PCN locates HEAD and NECK of pancreas who were randomized to ROBOTIC pancreaticoduodenectomy.
Patients with PCN locates HEAD and NECK of pancreas who were randomized to LAPAROSCOPIC pancreaticoduodenectomy.
Patients with PCN locates BODY and TAIL of pancreas who were randomized to ROBOTIC distal pancreatectomy.
Patients with PCN locates BODY and TAIL of pancreas who were randomized to LAPAROSCOPIC distal pancreatectomy.
Outcomes
Primary Outcome Measures
Complication Rate
The rate of frequency of Clavein-Dindo Grade II-IV complication
Secondary Outcome Measures
Postoperative length of stay
The mean of postoperative length of stay
VAS score
patients complain of pain after surgery, 0-10, 10 means the greatest pain
Grade B and C pancreatic fistula
The frequency of grade B or C pancreatic fistula
QOL score
Quality of life after surgery, greater means higher life satisfaction
Expense
The amount of treatment expense and certain procedure expense
90-day death rate
The rate of death within 90 days after surgery
The rate of spleen-preservation
For DP groups, the rate of spleen being preserved
Full Information
NCT ID
NCT05259384
First Posted
April 21, 2021
Last Updated
February 25, 2022
Sponsor
Peking Union Medical College Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05259384
Brief Title
Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms
Official Title
Comparison Between Robotic and Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 17, 2021 (Actual)
Primary Completion Date
April 30, 2024 (Anticipated)
Study Completion Date
October 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking Union Medical College Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Pancreatic cystic neoplasm (PCN) is a type of neoplastic lesion formed by the proliferation of pancreatic duct or acinar epithelial cells and retention of pancreatic secretions. The tumor can be located in the head and neck of the pancreas or the body and tail of the pancreas. Conventionally, open pancreaticoduodenectomy or open distal pancreatectomy was performed for patients with PCN locates either at the head or tail. In the ear of minimally invasive pancreatic surgery, when compared with open surgery, laparoscopic technology or Da Vinci robotic technology can avoid some open procedures limitations.
Here we design this prospective randomized clinical trial to compare robotic surgery to laparoscopic surgery for the treatment of PCN and verify the safety and feasibility of both two minimally invasive procedures.
Detailed Description
Background: Pancreatic cystic neoplasm (PCN) is a type of neoplastic lesion formed by the proliferation of pancreatic duct or acinar epithelial cells and retention of pancreatic secretions. Its heterogeneity is large, which can be benign, borderline, and poor differentiation and even evolve into pancreatic cancer. The tumor can be located in the head and neck of the pancreas or the body and tail of the pancreas. Some patients may be accompanied by recurrent pancreatitis, abdominal pain, nausea, vomiting, jaundice, and other gastrointestinal symptoms, usually with the help of abdominal ultrasound and endoscopy, ERCP, CT, nuclear magnetic, or MRCP imaging The examination can diagnose the disease. For PCN patients with large tumors, risk of malignant transformation, and accompanying symptoms that affect the quality of life, surgery is an effective treatment.
Based on the conventional routine treatment, open pancreaticoduodenectomy or open distal pancreatectomy was performed for patients with PCN locates either at the head or tail.
After more than 20 years of development, minimally invasive pancreatic surgery technology can be divided into two categories: laparoscopic technology and Da Vinci robotic technology. In general, compared with open surgery, minimally invasive pancreatic surgery technology can avoid some open procedures limitations, reduce the loss of intraoperative body fluid and its impact on the internal environment, and avoid excessive disturbance to other abdominal organs. It also helps reduce the pain of patients and shorten the length of hospital stay. Because most PCNs are benign or borderline tumors, such patients are eligible for minimally invasive pancreatic surgery.
Aim and Hypothesis: Here we design this prospective randomized clinical trial to compare robotic surgery to laparoscopic surgery for the treatment of PCN and verify the safety and feasibility of both two minimally invasive procedures. We conduct a single-center prospective randomized clinical trial to compare the outcomes of different minimally invasive techniques.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Neoplasm
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The enrolled candidates will be split into two subgroups(PD group or DP group) based on the location of their neoplasms. Every subgroups will be divided into two parallel groups by the randomization of intervention plan(lap surgery or robotic surgery)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
MIPD-ROB
Arm Type
Experimental
Arm Description
Patients with PCN locates HEAD and NECK of pancreas who were randomized to ROBOTIC pancreaticoduodenectomy.
Arm Title
MIPD-LAP
Arm Type
Active Comparator
Arm Description
Patients with PCN locates HEAD and NECK of pancreas who were randomized to LAPAROSCOPIC pancreaticoduodenectomy.
Arm Title
MIDP-ROB
Arm Type
Experimental
Arm Description
Patients with PCN locates BODY and TAIL of pancreas who were randomized to ROBOTIC distal pancreatectomy.
Arm Title
MIDP-LAP
Arm Type
Active Comparator
Arm Description
Patients with PCN locates BODY and TAIL of pancreas who were randomized to LAPAROSCOPIC distal pancreatectomy.
Intervention Type
Procedure
Intervention Name(s)
Robotic pancreaticoduodenectomy
Intervention Description
The Intervention of MIPD-ROB group
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic pancreaticoduodenectomy
Intervention Description
The Intervention of MIPD-LAP group
Intervention Type
Procedure
Intervention Name(s)
Robotic Distal Pancreatectomy
Intervention Description
The Intervention of MIDP-ROB group
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic Distal Pancreatectomy
Intervention Description
The Intervention of MIDP-LAP group
Primary Outcome Measure Information:
Title
Complication Rate
Description
The rate of frequency of Clavein-Dindo Grade II-IV complication
Time Frame
up to 90 days
Secondary Outcome Measure Information:
Title
Postoperative length of stay
Description
The mean of postoperative length of stay
Time Frame
during the treatment
Title
VAS score
Description
patients complain of pain after surgery, 0-10, 10 means the greatest pain
Time Frame
up to 90 days
Title
Grade B and C pancreatic fistula
Description
The frequency of grade B or C pancreatic fistula
Time Frame
up to 90 days
Title
QOL score
Description
Quality of life after surgery, greater means higher life satisfaction
Time Frame
up to 90 days
Title
Expense
Description
The amount of treatment expense and certain procedure expense
Time Frame
during the treatment
Title
90-day death rate
Description
The rate of death within 90 days after surgery
Time Frame
up to 90 days
Title
The rate of spleen-preservation
Description
For DP groups, the rate of spleen being preserved
Time Frame
up to 90 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years old or older;
Diagnosed as PCN;
Patients with head or neck PCNs are eligible for minimal invasive PD, or patients with distal PCNs are eligible for minimal invasive DP.
Exclusion Criteria:
Not a PCN base on the sample's pathology;
Procedure change from MIDP/MIPD to others during the operation;
ASA more than 4;
Patients or families deny certain treatment.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hanyu Zhang, M.D.
Phone
01069152600
Email
medzhy5813@126.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
MENGHUA Dai, M.D.
Organizational Affiliation
Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Official's Role
Study Chair
Facility Information:
Facility Name
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
City
Beijing
ZIP/Postal Code
100730
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Menghua Dai, M.D.
Email
daimh@pumch.cn
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms
We'll reach out to this number within 24 hrs